Snacktivity to promote physical activity WP4

A multi-centre, open-label, two-arm, parallel group, individually randomised trial, with an internal pilot and economic evaluation, to test the superiority of Snacktivity compared with usual care

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN12390945

Enrollment

900

Registered

2024-03-22

Start date

2024-05-27

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Physical activity Other

Interventions

The trial is a multi-centre, randomized, open-label, two-arm, individually randomised, parallel-group, superiority trial with an internal pilot and economic evaluation. The trial aims to recruit 724 i

2. Adherence to Snacktivity™: Defined as a participant achieving a minimum of four bouts of MVPA lasting =2 minutes (i.e., activity snacks) on average each day over 12 weeks as per the feasibility tr

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Completes =18 years (all routes of recruitment) 4. Own a mobile phone capable of hosting apps (Apple iOS 13.0+ and Android 4.3+) 5. Agreement for their healthcare professional (HCP) to be notified of their involvement in the trial

Exclusion criteria

Exclusion criteria: 1. Unable to understand English sufficiently to complete the trial assessments 2. Women known to be pregnant or breastfeeding 3. Inpatient, bedbound or unable to complete physical activity

Design outcomes

Primary

Measure	Time frame
Average weekly moderate to vigorous physical activity (MVPA) measured using the Axivity (AX3) device at 12 months	—

Secondary

Measure	Time frame
1. The proportion of participants meeting the guidance amount of 150 minutes of MVPA per week measured using the using the Axivity (AX3) device at baseline, 3 and 12 months 2. Average total minutes (sum of light, moderate and vigorous) of physical activity per day measured using the Axivity (AX3) device at baseline, 3 and 12 months 3. Average number of minutes of light, moderate and vigorous physical activity per day measured using the Axivity (AX3) device at baseline, 3 and 12 months 4. Average minutes of MVPA accumulated in bouts lasting =2, =5 and = 10 minutes per day measured using the Axivity (AX3) device at baseline, 3 and 12 months 5. Average number of MVPA bouts lasting =2, =5 and = 10 minutes per day measured using the Axivity (AX3) device at baseline, 3 and 12 months 6. Average magnitude of dynamic wrist acceleration per day (as a proxy for the total volume of activity) measured using the Axivity (AX3) device at baseline, 3 and 12 months 7. Average intensity gradient per day (no unit for this variable) measured using the Axivity (AX3) device at baseline, 3 and 12 months 8. Average minutes of sedentary time per day measured using the Axivity (AX3) device at baseline, 3 and 12 months 9. Average time (minutes) spent in prolonged sedentary behaviour per day measured using the Axivity (AX3) device at baseline, 3 and 12 months 10. Average number of prolonged sedentary bouts per day measured using the Axivity (AX3) device at baseline, 3 and 12 months 11. Average sleep duration (mins/day) and average efficiency (quality) (%/day) measured using the Axivity (AX3) device at baseline, 3 and 12 months The researchers will also assess: 1. Weight (objective [or self-reported if the participant is unable to provide objective weight]) at baseline, 3 and 12 months 2. Depression/anxiety measured using the Hospital Anxiety and Depression Scale (HADS)) at baseline, 3 and 12 months 3. Quality of life measured using the EQ-5D-5L questionnaire at baseline, 3 and 12 months 4. Se	—

Measure

Time frame

1. The proportion of participants meeting the guidance amount of 150 minutes of MVPA per week measured using the using the Axivity (AX3) device at baseline, 3 and 12 months 2. Average total minutes (sum of light, moderate and vigorous) of physical activity per day measured using the Axivity (AX3) device at baseline, 3 and 12 months 3. Average number of minutes of light, moderate and vigorous physical activity per day measured using the Axivity (AX3) device at baseline, 3 and 12 months 4. Average minutes of MVPA accumulated in bouts lasting =2, =5 and = 10 minutes per day measured using the Axivity (AX3) device at baseline, 3 and 12 months 5. Average number of MVPA bouts lasting =2, =5 and = 10 minutes per day measured using the Axivity (AX3) device at baseline, 3 and 12 months 6. Average magnitude of dynamic wrist acceleration per day (as a proxy for the total volume of activity) measured using the Axivity (AX3) device at baseline, 3 and 12 months 7. Average intensity gradient per day (no unit for this variable) measured using the Axivity (AX3) device at baseline, 3 and 12 months 8. Average minutes of sedentary time per day measured using the Axivity (AX3) device at baseline, 3 and 12 months 9. Average time (minutes) spent in prolonged sedentary behaviour per day measured using the Axivity (AX3) device at baseline, 3 and 12 months 10. Average number of prolonged sedentary bouts per day measured using the Axivity (AX3) device at baseline, 3 and 12 months 11. Average sleep duration (mins/day) and average efficiency (quality) (%/day) measured using the Axivity (AX3) device at baseline, 3 and 12 months The researchers will also assess: 1. Weight (objective [or self-reported if the participant is unable to provide objective weight]) at baseline, 3 and 12 months 2. Depression/anxiety measured using the Hospital Anxiety and Depression Scale (HADS)) at baseline, 3 and 12 months 3. Quality of life measured using the EQ-5D-5L questionnaire at baseline, 3 and 12 months 4. Se

—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 6, 2026